Literature DB >> 17465015

Application of polarity switching in the identification of the metabolites of RO9237.

William L Fitch1, Limin He, Ya-Ping Tu, Ludmila Alexandrova.   

Abstract

Polarity switching mass spectrometry is an efficient way to collect structural data on drug metabolites. The value of this approach is illustrated with the in vitro metabolism of RO9237. Metabolites are identified by positive and negative electrospray ionization (ESI) full scan mass spectrometry, MS/MS and MS(3) using unlabelled and (14)C-radiolabelled versions of the drug. Comparison of the relative detectability of these metabolites by +ESI and -ESI shows that neither ESI mode is universal. It is advantageous to screen for metabolites using both positive and negative ionization modes. This is especially true for phase II metabolism which tends to make molecules more polar and often more acidic. Identification of phase II metabolites also benefits greatly from MS(3) experiments because the conjugating groups typically are cleaved in MS/MS and information on the core structure is only obtained in MS(3). A special case of phase II metabolism is the generation of glutathione (GSH) conjugates from reactive metabolites. The detection of GSH conjugates also benefits from generating both positive and negative ESI mass spectral data.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465015     DOI: 10.1002/rcm.3009

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  2 in total

1.  Elimination of benzene from protonated N-benzylindoline: benzyl cation/proton transfer or direct proton transfer?

Authors:  Cheng Guo; Lei Yue; Mengzhe Guo; Kezhi Jiang; Yuanjiang Pan
Journal:  J Am Soc Mass Spectrom       Date:  2013-01-30       Impact factor: 3.109

2.  Enhancing Metabolomic Coverage in Positive Ionization Mode Using Dicationic Reagents by Infrared Matrix-Assisted Laser Desorption Electrospray Ionization.

Authors:  Ying Xi; David C Muddiman
Journal:  Metabolites       Date:  2021-11-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.